AptarGroup Contract to Enhance Sterilization Technology
AptarGroup, Inc. (NYSE: ATR), a frontrunner in drug and consumer product solutions, recently announced the receipt of a significant contract from the U.S. Federal Government. This award is aimed at accelerating the development of its innovative ActivShield™ technology, which provides a power-free method for sterilizing medical devices and instruments. The versatility of this solution makes it particularly valuable across various settings, from rural areas to military environments and healthcare facilities lacking robust sterilization capabilities.
Understanding ActivShield™ Technology
The ActivShield™ technology is built on more than 20 years of material science expertise from Aptar CSP Technologies. It utilizes the company's trusted 3-Phase Activ-Polymer™ platform, recognized for its reliability in protecting sensitive drug products and various medical devices. This innovative technology stands out as it does not rely on traditional infrastructure, power, or extensive training for operation.
Innovative Sterilization Process
One of the key advantages of ActivShield™ is its ability to emit a controlled amount of chlorine dioxide gas for effective sterilization. This process ensures the elimination of harmful pathogens while avoiding the health risks associated with conventional methods, such as Ethylene Oxide (EtO). The portable nature of ActivShield™ allows for easy application in challenging conditions where sterilization resources are typically scarce.
Impact on Healthcare and Military
Stephan B. Tanda, President and CEO of Aptar, expressed the company's pride in collaborating with the government to enhance this groundbreaking technology. The goal is to ensure that medical devices and instruments can be efficiently sterilized in locations where traditional power sources are unavailable, thereby extending the usage and applicability of this technology.
Aptar's custom-engineered solutions can meet varied requirements, ensuring stability throughout the product's shelf life. The compact design facilitates easy storage and transportation, which is crucial in emergency and remote settings.
Reducing Infection Risks
This technology also aims to address critical needs in civilian emergency response scenarios, significantly minimizing infection risks from inadequately sterilized items. Moreover, the military can benefit immensely from ActivShield™, providing crucial access to sterilized medical instruments during emergencies, especially in areas far from traditional healthcare facilities.
Future Potential of ActivShield™
John Belfance, the president of Aptar CSP Technologies, highlighted that ActivShield™ represents a significant breakthrough in sterilization methods, especially for high-stakes environments requiring reliable instrument sterilization. The company's gratitude for the government’s recognition underscores the promising future of this technology in transforming sterilization processes.
The five-year contract awarded is valued at an approximate $4.8 million, emphasizing the government's commitment to enhancing medical safety through innovative solutions like ActivShield™.
About AptarGroup, Inc.
AptarGroup, Inc. plays a pivotal role as a global leader in drug and consumer product dosing, dispensing, and protection technologies. Its diverse market presence spans pharmaceuticals, beauty, food, beverage, personal care, and home care products. With a commitment to innovation, Aptar combines its material science expertise with robust engineering capabilities to translate ideas into market opportunities, enhancing the quality of life for consumers and patients alike.
With comprehensive services that include product design, global production, and regulatory support, Aptar ensures an expedited speed-to-market for its innovations. This dedication reinforces the company's mission to remain at the forefront of technology that serves our everyday needs.
Frequently Asked Questions
What is ActivShield™ technology?
ActivShield™ is a novel sterilization technology that does not require power or extensive training, using chlorine dioxide gas for the sterilization of medical devices.
Who awarded the contract for ActivShield™ technology?
The U.S. Federal Government awarded the contract to AptarGroup, Inc. to develop the ActivShield™ technology further.
What are the benefits of ActivShield™?
This technology reduces infection risks, eliminates reliance on harmful sterilization methods, and is portable for diverse applications in remote and emergency settings.
What is the value of the federal contract?
The federal contract awarded to AptarGroup is valued at approximately $4.8 million.
How does Aptar ensure product quality?
Aptar employs rigorous engineering and regulatory processes to guarantee the safety and reliability of its products, including ActivShield™ technology.
